This article was originally published in The Gray Sheet
Executive SummaryExcimer laser manufacturers renew vows for merger; the latest agreement calls for Advanced Interventional Systems (LAIS) shareholders to receive .80282 shares of Spectranetics stock for each LAIS share, giving them 45% ownership of the new company. The merger, subject to "customary conditions" and shareholder approval, is expected to close in four months. Following the merger, Spectranetics' President and CEO Robert DePasqua would serve as President, CEO and a director of the new firm, while LAIS director David Goldsmith would serve as chairman. AIS Chairman and CEO Robert Wall has resigned. An earlier acquisition offer by Spectranetics and merger proposal by LAIS, which were floated after an initial merger agreement fell through, were terminated in December ("The Gray Sheet" Dec. 20, In Brief)
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.